Imbria Pharmaceuticals
Cardiac mitotropes (fatty-acid-oxidation modulators)
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Ninerafaxstat(IMB-101) | Phase 2 | Cardiac fatty-acid oxidationSmall molecule | Heart FailureHypertrophic Cardiomyopathy |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT07023614 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.